Document is current
Any future updates will be listed below
-
Authors
Ichikawa, David M. https://orcid.org/0000-0002-7517-5150
Abdin, Osama https://orcid.org/0000-0002-5471-2906
Alerasool, Nader
Kogenaru, Manjunatha https://orcid.org/0000-0001-6570-7857
Mueller, April L. https://orcid.org/0000-0002-2134-5134
Wen, Han https://orcid.org/0000-0003-4680-4218
Giganti, David O.
Goldberg, Gregory W. https://orcid.org/0000-0002-5022-9976
Adams, Samantha
Spencer, Jeffrey M. https://orcid.org/0000-0003-4690-2432
Razavi, Rozita
Nim, Satra
Zheng, Hong
Gionco, Courtney
Clark, Finnegan T. https://orcid.org/0000-0003-0575-7312
Strokach, Alexey
Hughes, Timothy R. https://orcid.org/0000-0002-8721-4719
Lionnet, Timothee https://orcid.org/0000-0003-1508-0202
Taipale, Mikko https://orcid.org/0000-0003-3811-1761
Kim, Philip M. https://orcid.org/0000-0003-3683-152X
Noyes, Marcus B. https://orcid.org/0000-0002-3065-1096
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (RGM118851A1, RGM118851A1, RGM118851A1, RGM118851A1, RGM118851A1, RGM118851A1, RGM118851A1, RGM118851A1, RGM118851A1, RGM118851A1)
- License Information
-
More Information
Article History
Received: 5 November 2021
Accepted: 17 November 2022
First Online: 26 January 2023
Competing interests
: M.T., P.M.K. and M.B.N. are founders of TBG Therapeutics. Intellectual property has been filed on the method for generation of ZFs, the design model and the method to reprogram TFs. The remaining authors declare no competing interests.
